Related Experiment Videos
Intraocular 9-([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival
Ophthalmic Surgery
|July 1, 1986
Summary
This study shows that intravitreal injections of a new antiviral, 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine, maintain effective levels in rabbits. These levels are sufficient to combat human cytomegalovirus infections.
Area of Science:
- Ophthalmology
- Virology
- Pharmacology
Background:
- Human cytomegalovirus (CMV) infections can cause severe ocular complications.
- Current treatment options for CMV retinitis may have limitations.
Purpose of the Study:
- To evaluate the ocular pharmacokinetics and antiviral activity of 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine after intravitreal injection.
- To assess the potential of this novel antiviral for treating CMV-related eye diseases.
Main Methods:
- Intravitreal injections of 400 micrograms of 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine were administered to rabbits.
- Antiviral levels in ocular tissues were measured at 60 hours post-injection.
- In vitro ID50 values for various human CMV strains were determined.
Main Results:
- Detectable levels of the antiviral were present in rabbit eyes at 60 hours after intravitreal administration.
- The observed antiviral concentrations exceeded the in vitro median inhibitory dose (ID50) for several human CMV strains.
Conclusions:
- Intravitreal 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine demonstrates promising ocular persistence and antiviral activity.
- This antiviral agent may offer a therapeutic strategy for acute retinal necrosis and CMV retinitis in AIDS patients.